AbbVie (ABBV)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-15
$263.04+0.49%
Close 2026-09-15 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-15
Research Workspace
Put ABBV beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Increase adjusted diluted EPS to at least $14.28 in 2026: FY26 EPS guide $13.97 vs $14.28 target (-2.2%).
View ThesisRevenue growth is accelerating — up about 10% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 11%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskAbbVie must continue to advance its immunology portfolio to justify its current price. Revenue growth remains strong, with Q2 2026 revenue of about $17 billion, up 10% year over year. It trades at 24× P/E versus a peer median of 22×, indicating it looks expensive based on current multiples. The primary risk is missing the adjusted diluted EPS guidance of at least $14.28 for 2026, as the current guidance is mid $13.97, missing by 2.2%. Peer multiples imply a price about 9% below where it trades.
Trailing returns as of 2026-09-15. ABBV is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 31 analysts currently covering ABBV (as of Sep 2026).
Based on 12 Wall Street analysts offering 12-month price targets for ABBV in the last 4 months.
Continue this research
Compare ABBV with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ABBV Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-09-15. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put ABBV next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance immunology portfolio growth and pipeline expansion
Apogee deal enhances immunology portfolio growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-15. EPS is implied from price ÷ P/E. Not investment advice.
Current $263.04
The last 12 months of price, then the range of analyst 12-month targets from today’s $263.04.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Advance immunology portfolio growth and pipeline expansion
Acquisition supports immunology portfolio growth and pipeline expansion.
Threatens: Maintain and grow dividend payouts
Humira's decline may impact dividend sustainability.
Advances: Advance immunology portfolio growth and pipeline expansion
Positive results enhance immunology portfolio growth potential.
Advances: Advance immunology portfolio growth and pipeline expansion
Positive trial results support immunology portfolio growth.
Advances: Advance immunology portfolio growth and pipeline expansion
Oncology innovation aligns with immunology portfolio growth.
Advances: Advance immunology portfolio growth and pipeline expansion
New data supports immunology portfolio growth and pipeline expansion.
Lung cancer data supports pipeline expansion in oncology.
